Apelin fusion proteins and uses thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsPanayiotis Stevis, Andrew Murphy
Life of this patent
Estimating the term…
Abstract
The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or a variant of an Fc domain. Apelin Fc-fusion polypeptides are capable of binding to the apelin receptor (APLNR). Apelin Fc-fusion polypeptides are capable of activating the APLNR and have improved pharmacokinetic properties compared to apelin peptides that are not fused to an Fc or an Fc fragment. Apelin Fc-fusion polypeptides are useful in diseases and conditions related to cardiovascular function, diabetes, cancer, obesity and other apelin-related conditions.
Claims48
A polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or variant of an Fc domain.
An apelin receptor (APNLR) binding molecule comprising:
- a. an apelin peptide component,
- b. a human IgG Fc domain, and
- c. at least one linker component.
A composition comprising the receptor binding molecule of 27.
A composition comprising the receptor binding molecule of 28.
Dependencies are inferred from the claim text.